4-methyl-N-{2-[4-(trifluoromethyl)phenyl]ethyl}aniline | 1111734-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-N-{2-[4-(trifluoromethyl)phenyl]ethyl}aniline
• 英文别名: p-tolyl-[2-(4-trifluoromethyl-phenyl)-ethyl]-amine；4-methyl-N-[2-[4-(trifluoromethyl)phenyl]ethyl]aniline
• CAS: 1111734-49-6
• 化学式: C₁₆H₁₆F₃N
• 分子量: 279.305
• InChiKey: KKKQHYNYDCJYSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-methyl-N-{2-[4-(trifluoromethyl)phenyl]ethyl}aniline 、 N-Boc-DL-苯基甘氨酸 生成 2-amino-2-phenyl-N-p-tolyl-N-[2-(4-trifluoromethyl-phenyl)-ethyl]-acetamide
  参考文献：
  名称：

  MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及式I的化合物，其中Ar，R1，R2，R3，R4，R5，n，o和p如本文所定义，或其药学适用的酸盐加合物，光学纯对映体，外消旋体或其二对映异构体混合物。式I的化合物可用于治疗睡眠障碍，如睡眠呼吸暂停，嗜睡症，失眠，睡眠障碍，时差综合症，昼夜节律紊乱或与神经系统疾病相关的睡眠障碍。

  公开号：

  US20090036422A1
• 作为产物：
  描述：

  在 sodium cyanoborohydride 、 zinc(II) chloride 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 20.0h， 以583 mg的产率得到4-methyl-N-{2-[4-(trifluoromethyl)phenyl]ethyl}aniline
  参考文献：
  名称：

  一种用于炔烃加氢胺化的（氨基嘧啶基）钛催化剂

  摘要：

  一种新的（氨基嘧啶合）钛络合物已由廉价且易于获得的 2-（叔丁基氨基）嘧啶和 [Ti(NMe2)4] 合成，并用作炔烃分子间加氢胺化以及氨基烯烃环化的催化剂。1-苯基丙炔和末端芳基炔烃的加氢胺化反应以优异的产率和区域选择性提供相应的反马尔科夫尼科夫加成产物。

  DOI：

  10.1002/ejoc.201301004

文献信息

• Merging Photoinduced Iron-Catalyzed Decarboxylation with Copper Catalysis for C–N and C–C Couplings
  作者：Ni Xiong、Yang Li、Rong Zeng

  DOI：10.1021/acscatal.2c05293

  日期：2023.2.3

  dual-catalytic strategy for the radical decarboxylation functionalization of aliphatic carboxylic acids. The photoinduced ligand-to-iron charge transfer process under light was initially occurred to generate an unstabilized alkyl radical, and the copper catalyst delivered the radical and enabled the subsequent coupling reactions to form C–N or C–C bonds. By merging iron-catalyzed decarboxylation with copper catalysis

  我们报告了一种用于脂肪族羧酸自由基脱羧功能化的光诱导铁/铜双催化策略。光诱导配体到铁的电荷转移过程最初是为了产生不稳定的烷基自由基，铜催化剂传递自由基并使随后的偶联反应形成 C-N 或 C-C 键。通过将铁催化脱羧与铜催化相结合，该系统可以顺利转化各种脂肪族羧酸，从而有效地进行胺化、脱羧脱氢和烷基化。适用于多种复杂的药物或天然分子，表明该策略将有助于快速合成化合物库并有利于药物的发现。
• GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd.

  公开号：EP3763728A1

  公开（公告）日：2021-01-13

  The present invention discloses glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I), The present invention also provides a preparation method for and an application of the glycopeptide compounds. Upon testing, compared with a second-generation glycopeptide drug oritavancin, the glycopeptide antibiotic compounds have higher inhibition activity on drug-resistant bacterial strains, especially MRSA or VRE. Further testing shows that most of the glycopeptide compounds have safety higher than that of oritavancin and can be prepared into drugs for treating or preventing diseases caused by various bacterial infections, such as skin and soft tissue infections, meningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, and empyema,

  本发明公开了具有抗耐药性细菌活性的糖肽化合物，符合通式（I）所代表的糖肽化合物、 本发明还提供了糖肽化合物的制备方法和应用。经测试，与第二代糖肽药物奥利他万星（oritavancin）相比，糖肽抗生素化合物对耐药菌株，尤其是 MRSA 或 VRE 具有更高的抑制活性。进一步的测试表明，大多数糖肽化合物的安全性高于奥利他万星，可以制备成药物，用于治疗或预防各种细菌感染引起的疾病，如皮肤和软组织感染、脑膜炎、败血症、肺炎、关节炎、腹膜炎、支气管炎和肺水肿、
• Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof
  申请人：Shanghai LaiYi Center For Biopharmaceutical R&D Co

  公开号：US20210093691A1

  公开（公告）日：2021-04-01

  The present invention discloses glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I), The present invention also provides a preparation method for and an application of the glycopeptide compounds. Upon testing, compared with a second-generation glycopeptide drug oritavancin, the glycopeptide antibiotic compounds have higher inhibition activity on drug-resistant bacterial strains, especially MRSA or VRE. Further testing shows that most of the glycopeptide compounds have safety higher than that of oritavancin and can be prepared into drugs for treating or preventing diseases caused by various bacterial infections, such as skin and soft tissue infections, meningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, and empyema.
• [EN] MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS MONOAMIDE EN TANT QU'ANTAGONISTES DE RÉCEPTEURS AUX ORÉXINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009016087A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds of formula (I), wherein Ar is aryl or heteroaryl; R1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, SO2-lower alkyl or hydroxy; R2 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, S-lower alkyl, SO2-lower alkyl, NO2 or hydroxy; R3 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, -(CH2)m-O-lower alkyl, lower alkoxy substituted by halogen, 3-hydroxy-oxetan-3-yl, cyano or SO2-lower alkyl; or if o is 2, R3 may form in 3 and 4 position together with the carbon atoms to which they are attached an addional ring with the groups -O-CH2-O-, -O-CF2-CF2-O-, -N=CH-S-, -O-CF2-O-, -(CH2)4-, -NH-C(O)-NH-, -O-(CH2)2- or _(CH2)2-O-; R4/R5 are independently from each other hydrogen, -(CR'2)mOH, lower alkyl, lower alkoxy, -NRR', or is -(CH2)0,1-heterocycloalkyl, optionally substituted by hydroxy, or R4 and R5 are together =O or =N-OH,; R/R' are independently from each other hydrogen, lower alkyl, C(O)H, -(CR'2)m-OH, -(CR'2)m-NR'2, -(CR'2)m-NR'-C(O)-lower alkyl, -(CR'2)m-O-lower alkyl, -(CR'2)m-O-lower alkenyl, -C(O)O-lower alkyl, -C(O)-CR'2-NH-C(O)O-lower alkyl, -C(O)-CR'2-NR'2, or is -(CH2)0,1-heterocycloalkyl or -(CH2)0,1-furan-2-yl; R' are independently from each other hydrogen, lower alkoxy, phenyl or lower alkyl; n is 1, 2, 3 or 4; o is 1, 2 or 3; p is 1, 2 or 3; m is 1, 2 or 3; or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula (I) may be used for example for the treatment of the sleep disorders, which are sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.